Hmdb loader
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2012-09-06 15:16:52 UTC
Update Date2022-03-07 02:51:58 UTC
HMDB IDHMDB0015381
Secondary Accession Numbers
  • HMDB15381
Metabolite Identification
Common NameGliquidone
DescriptionGliquidone, also known as glurenorm or beglynora, belongs to the class of organic compounds known as 1,3-isoquinolinediones. These are isoquinoline derivatives carrying one C=O group at positions 1, and 3 respectively. It is classified as a second-generation sulfonylurea. Gliquidone is a drug which is used in the treatment of diabetes mellitus type 2. Gliquidone is an extremely weak basic (essentially neutral) compound (based on its pKa). It is used in the treatment of diabetes mellitus type 2. It is marketed by the pharmaceutical company Boehringer Ingelheim (Germany). Its metabolites are excreted virtually completely with bile (even with long-term administration), thus allowing the use of medication in diabetic patients suffering from kidney disease and diabetic nephropathy. Allergy to sulfonylureas or sulfonamidesDiabetes mellitus type 1Diabetic ketoacidosisPatients that underwent removal of the pancreasAcute porphyriaSevere liver disease accompanying with liver insufficiencySeveral conditions (e.g., infectious diseases or major surgical intervention), when insulin administration is requiredPregnancy or breastfeedingGliquidone is fully metabolized by the liver. Gliquidone (INN, sold under the trade name Glurenorm) is an anti-diabetic medication in the sulfonylurea class.
Structure
Data?1582753290
Synonyms
ValueSource
GlurenormKegg
Sanofi synthelabo brand OF gliquidoneHMDB
GlikvidonHMDB
Gliquidone, monosodium saltHMDB
AR-DF 26HMDB
BeglynoraHMDB
Yamanouchi brand OF gliquidoneHMDB
BeglynorHMDB
GlurenorHMDB
Gliquidone, calcium saltHMDB
GlycvidonHMDB
N'-cyclohexyl-N-{4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]benzenesulfonyl}carbamimidateHMDB
N'-cyclohexyl-N-{4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]benzenesulphonyl}carbamimidateHMDB
N'-cyclohexyl-N-{4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]benzenesulphonyl}carbamimidic acidHMDB
Chemical FormulaC27H33N3O6S
Average Molecular Weight527.632
Monoisotopic Molecular Weight527.209006493
IUPAC Name1-cyclohexyl-3-{4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]benzenesulfonyl}urea
Traditional Namegliquidone
CAS Registry Number33342-05-1
SMILES
COC1=CC2=C(C=C1)C(C)(C)C(=O)N(CCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1)C2=O
InChI Identifier
InChI=1S/C27H33N3O6S/c1-27(2)23-14-11-20(36-3)17-22(23)24(31)30(25(27)32)16-15-18-9-12-21(13-10-18)37(34,35)29-26(33)28-19-7-5-4-6-8-19/h9-14,17,19H,4-8,15-16H2,1-3H3,(H2,28,29,33)
InChI KeyLLJFMFZYVVLQKT-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as 1,3-isoquinolinediones. These are isoquinoline derivatives carrying one C=O group at positions 1, and 3 respectively.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIsoquinolines and derivatives
Sub Class1,3-isoquinolinediones
Direct Parent1,3-isoquinolinediones
Alternative Parents
Substituents
  • 1,3-isoquinolinedione
  • Isoquinolone
  • Tetrahydroisoquinoline
  • Benzenesulfonamide
  • Benzenesulfonyl group
  • Anisole
  • Alkyl aryl ether
  • Sulfonylurea
  • Monocyclic benzene moiety
  • Benzenoid
  • Carboxylic acid imide, n-substituted
  • Carboxylic acid imide
  • Dicarboximide
  • Aminosulfonyl compound
  • Sulfonyl
  • Organosulfonic acid or derivatives
  • Organic sulfonic acid or derivatives
  • Carboximidic acid derivative
  • Carboxylic acid derivative
  • Azacycle
  • Organic 1,3-dipolar compound
  • Ether
  • Propargyl-type 1,3-dipolar organic compound
  • Organopnictogen compound
  • Organic oxygen compound
  • Organic nitrogen compound
  • Carbonyl group
  • Organic oxide
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Organooxygen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Ontology
Physiological effectNot Available
Disposition
ProcessNot Available
RoleNot Available
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting Point181 °CNot Available
Boiling PointNot AvailableNot Available
Water Solubility0.0022 g/LNot Available
LogP4.5Not Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.0022 g/LALOGPS
logP3.59ALOGPS
logP4.14ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)4.32ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area121.88 ŲChemAxon
Rotatable Bond Count6ChemAxon
Refractivity139.48 m³·mol⁻¹ChemAxon
Polarizability57.26 ųChemAxon
Number of Rings4ChemAxon
BioavailabilityYesChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DarkChem[M+H]+220.54331661259
DarkChem[M-H]-217.22631661259
DeepCCS[M+H]+224.17730932474
DeepCCS[M-H]-221.78130932474
DeepCCS[M-2H]-254.66630932474
DeepCCS[M+Na]+230.08930932474
AllCCS[M+H]+222.132859911
AllCCS[M+H-H2O]+220.732859911
AllCCS[M+NH4]+223.432859911
AllCCS[M+Na]+223.832859911
AllCCS[M-H]-208.832859911
AllCCS[M+Na-2H]-210.532859911
AllCCS[M+HCOO]-212.632859911

Predicted Retention Times

Underivatized

Chromatographic MethodRetention TimeReference
Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022.7.82 minutes32390414
Predicted by Siyang on May 30, 202214.8699 minutes33406817
Predicted by Siyang using ReTip algorithm on June 8, 20221.54 minutes32390414
Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid2780.9 seconds40023050
Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid205.8 seconds40023050
Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid222.5 seconds40023050
Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid182.1 seconds40023050
RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid169.7 seconds40023050
Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid583.0 seconds40023050
BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid607.1 seconds40023050
HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate)158.7 seconds40023050
UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid1266.6 seconds40023050
BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid597.9 seconds40023050
UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid1713.7 seconds40023050
SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid367.0 seconds40023050
RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid407.1 seconds40023050
MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate286.0 seconds40023050
KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA197.0 seconds40023050
Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water18.3 seconds40023050

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
GliquidoneCOC1=CC2=C(C=C1)C(C)(C)C(=O)N(CCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1)C2=O5924.1Standard polar33892256
GliquidoneCOC1=CC2=C(C=C1)C(C)(C)C(=O)N(CCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1)C2=O3500.1Standard non polar33892256
GliquidoneCOC1=CC2=C(C=C1)C(C)(C)C(=O)N(CCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1)C2=O4407.7Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Gliquidone,1TMS,isomer #1COC1=CC=C2C(=C1)C(=O)N(CCC1=CC=C(S(=O)(=O)N(C(=O)NC3CCCCC3)[Si](C)(C)C)C=C1)C(=O)C2(C)C4146.0Semi standard non polar33892256
Gliquidone,1TMS,isomer #1COC1=CC=C2C(=C1)C(=O)N(CCC1=CC=C(S(=O)(=O)N(C(=O)NC3CCCCC3)[Si](C)(C)C)C=C1)C(=O)C2(C)C3864.4Standard non polar33892256
Gliquidone,1TMS,isomer #1COC1=CC=C2C(=C1)C(=O)N(CCC1=CC=C(S(=O)(=O)N(C(=O)NC3CCCCC3)[Si](C)(C)C)C=C1)C(=O)C2(C)C5634.9Standard polar33892256
Gliquidone,1TMS,isomer #2COC1=CC=C2C(=C1)C(=O)N(CCC1=CC=C(S(=O)(=O)NC(=O)N(C3CCCCC3)[Si](C)(C)C)C=C1)C(=O)C2(C)C4104.5Semi standard non polar33892256
Gliquidone,1TMS,isomer #2COC1=CC=C2C(=C1)C(=O)N(CCC1=CC=C(S(=O)(=O)NC(=O)N(C3CCCCC3)[Si](C)(C)C)C=C1)C(=O)C2(C)C3921.3Standard non polar33892256
Gliquidone,1TMS,isomer #2COC1=CC=C2C(=C1)C(=O)N(CCC1=CC=C(S(=O)(=O)NC(=O)N(C3CCCCC3)[Si](C)(C)C)C=C1)C(=O)C2(C)C5540.4Standard polar33892256
Gliquidone,2TMS,isomer #1COC1=CC=C2C(=C1)C(=O)N(CCC1=CC=C(S(=O)(=O)N(C(=O)N(C3CCCCC3)[Si](C)(C)C)[Si](C)(C)C)C=C1)C(=O)C2(C)C3951.0Semi standard non polar33892256
Gliquidone,2TMS,isomer #1COC1=CC=C2C(=C1)C(=O)N(CCC1=CC=C(S(=O)(=O)N(C(=O)N(C3CCCCC3)[Si](C)(C)C)[Si](C)(C)C)C=C1)C(=O)C2(C)C4112.7Standard non polar33892256
Gliquidone,2TMS,isomer #1COC1=CC=C2C(=C1)C(=O)N(CCC1=CC=C(S(=O)(=O)N(C(=O)N(C3CCCCC3)[Si](C)(C)C)[Si](C)(C)C)C=C1)C(=O)C2(C)C5326.5Standard polar33892256
Gliquidone,1TBDMS,isomer #1COC1=CC=C2C(=C1)C(=O)N(CCC1=CC=C(S(=O)(=O)N(C(=O)NC3CCCCC3)[Si](C)(C)C(C)(C)C)C=C1)C(=O)C2(C)C4429.2Semi standard non polar33892256
Gliquidone,1TBDMS,isomer #1COC1=CC=C2C(=C1)C(=O)N(CCC1=CC=C(S(=O)(=O)N(C(=O)NC3CCCCC3)[Si](C)(C)C(C)(C)C)C=C1)C(=O)C2(C)C4068.1Standard non polar33892256
Gliquidone,1TBDMS,isomer #1COC1=CC=C2C(=C1)C(=O)N(CCC1=CC=C(S(=O)(=O)N(C(=O)NC3CCCCC3)[Si](C)(C)C(C)(C)C)C=C1)C(=O)C2(C)C5629.7Standard polar33892256
Gliquidone,1TBDMS,isomer #2COC1=CC=C2C(=C1)C(=O)N(CCC1=CC=C(S(=O)(=O)NC(=O)N(C3CCCCC3)[Si](C)(C)C(C)(C)C)C=C1)C(=O)C2(C)C4372.7Semi standard non polar33892256
Gliquidone,1TBDMS,isomer #2COC1=CC=C2C(=C1)C(=O)N(CCC1=CC=C(S(=O)(=O)NC(=O)N(C3CCCCC3)[Si](C)(C)C(C)(C)C)C=C1)C(=O)C2(C)C4149.9Standard non polar33892256
Gliquidone,1TBDMS,isomer #2COC1=CC=C2C(=C1)C(=O)N(CCC1=CC=C(S(=O)(=O)NC(=O)N(C3CCCCC3)[Si](C)(C)C(C)(C)C)C=C1)C(=O)C2(C)C5529.5Standard polar33892256
Gliquidone,2TBDMS,isomer #1COC1=CC=C2C(=C1)C(=O)N(CCC1=CC=C(S(=O)(=O)N(C(=O)N(C3CCCCC3)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1)C(=O)C2(C)C4464.7Semi standard non polar33892256
Gliquidone,2TBDMS,isomer #1COC1=CC=C2C(=C1)C(=O)N(CCC1=CC=C(S(=O)(=O)N(C(=O)N(C3CCCCC3)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1)C(=O)C2(C)C4555.5Standard non polar33892256
Gliquidone,2TBDMS,isomer #1COC1=CC=C2C(=C1)C(=O)N(CCC1=CC=C(S(=O)(=O)N(C(=O)N(C3CCCCC3)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1)C(=O)C2(C)C5311.1Standard polar33892256
Spectra
Biological Properties
Cellular Locations
  • Membrane
Biospecimen Locations
  • Blood
  • Urine
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB01251 details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB01251 details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB01251
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID82719
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkGliquidone
METLIN IDNot Available
PubChem Compound91610
PDB IDNot Available
ChEBI ID441224
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General ReferencesNot Available

Enzymes

General function:
Involved in inward rectifier potassium channel activity
Specific function:
This potassium channel is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by external barium
Gene Name:
KCNJ8
Uniprot ID:
Q15842
Molecular weight:
47967.5
References
  1. Szewczyk A, Wojcik G, Lobanov NA, Nalecz MJ: The mitochondrial sulfonylurea receptor: identification and characterization. Biochem Biophys Res Commun. 1997 Jan 23;230(3):611-5. [PubMed:9015372 ]
  2. Sato T, Costa AD, Saito T, Ogura T, Ishida H, Garlid KD, Nakaya H: Bepridil, an antiarrhythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotection. J Pharmacol Exp Ther. 2006 Jan;316(1):182-8. Epub 2005 Sep 20. [PubMed:16174795 ]
  3. Hill RA, Rudra S, Peng B, Roane DS, Bounds JK, Zhang Y, Adloo A, Lu T: Hydroxyl-substituted sulfonylureas as potent inhibitors of specific [3H]glyburide binding to rat brain synaptosomes. Bioorg Med Chem. 2003 May 1;11(9):2099-113. [PubMed:12670661 ]
General function:
Involved in ATP binding
Specific function:
Putative subunit of the beta-cell ATP-sensitive potassium channel (KATP). Regulator of ATP-sensitive K(+) channels and insulin release
Gene Name:
ABCC8
Uniprot ID:
Q09428
Molecular weight:
177006.4
References
  1. Gribble FM, Ashcroft FM: Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism. 2000 Oct;49(10 Suppl 2):3-6. [PubMed:11078468 ]
  2. Harrower A: Gliclazide modified release: from once-daily administration to 24-hour blood glucose control. Metabolism. 2000 Oct;49(10 Suppl 2):7-11. [PubMed:11078469 ]
  3. Lawrence CL, Proks P, Rodrigo GC, Jones P, Hayabuchi Y, Standen NB, Ashcroft FM: Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia. 2001 Aug;44(8):1019-25. [PubMed:11484080 ]
  4. Reimann F, Ashcroft FM, Gribble FM: Structural basis for the interference between nicorandil and sulfonylurea action. Diabetes. 2001 Oct;50(10):2253-9. [PubMed:11574406 ]
  5. Proks P, Reimann F, Green N, Gribble F, Ashcroft F: Sulfonylurea stimulation of insulin secretion. Diabetes. 2002 Dec;51 Suppl 3:S368-76. [PubMed:12475777 ]